Pre-administration of PepFect6-microRNA-146a nanocomplexes inhibits inflammatory responses in keratinocytes and in a mouse model of irritant contact dermatitis
- 1 August 2016
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 235, 195-204
Abstract
No abstract availableKeywords
Funding Information
- European Regional Development Fund (SARMP12219T, 10.1-9/12/380 REMARK)
- Ministry of Education and Research (0180019s11, SF0180027s08)
- Eesti Teadusagentuur (PUT214, PUT4, PUT177, ETF8932)
- University of Tartu Developmental Fund (MV-1)
This publication has 42 references indexed in Scilit:
- Regulation of Monocyte Functional Heterogeneity by miR-146a and RelbCell Reports, 2012
- MicroRNAs, new effectors and regulators of NF‐κBImmunological Reviews, 2012
- MicroRNA-203 functions as a tumor suppressor in basal cell carcinomaOncogenesis, 2012
- miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in miceJournal of Experimental Medicine, 2011
- PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulationNucleic Acids Research, 2011
- Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivoNucleic Acids Research, 2011
- Function of miR-146a in Controlling Treg Cell-Mediated Regulation of Th1 ResponsesCell, 2010
- A New Potent Secondary Amphipathic Cell–penetrating Peptide for siRNA Delivery Into Mammalian CellsMolecular Therapy, 2009
- Multilevel Regulation of Gene Expression by MicroRNAsScience, 2008
- NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responsesProceedings of the National Academy of Sciences, 2006